One-Dimensional Rod-like Tobacco Mosaic Virus Promotes Macrophage Polarization for a Tumor-Suppressive Microenvironment.

The phenotype of tumor-associated macrophages plays an important role in their function of regulating the tumor immune microenvironment. The M1-phenotype macrophages display tumor-killing and immune activating functions. Here we show that the tobacco mosaic virus (TMV), a rod-like plant virus, can polarize macrophages to an M1 phenotype and shape a tumor-suppressive microenvironment. RAW 264.7 cells and bone marrow derived-macrophages (BMDMs) can recognize TMV via Toll-like receptor-4, and then the MAPK and NF-κB signaling pathways are activated, leading to the production of pro-inflammatory factors. Furthermore, the in vivo assessments on a subcutaneous co-injection tumor model show that the TMV-polarized BMDMs shape a tumor-suppressive microenvironment, resulting in remarkable delay of 4T1 tumor growth. Another in vivo assessment on an established tumor model indicates the high tumor-metastasis-inhibiting capacity of TMV-polarized BMDMs. This work suggests a role for this plant virus in macrophage-mediated therapeutic approaches and provides a strategy for tumor immunotherapy.

[1]  N. Steinmetz,et al.  Plant Viral Nanoparticle Conjugated with Anti-PD-1 Peptide for Ovarian Cancer Immunotherapy , 2021, International journal of molecular sciences.

[2]  P. Gimotty,et al.  Activating a collaborative innate-adaptive immune response to control metastasis. , 2021, Cancer cell.

[3]  M. Cam,et al.  Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape , 2021, Nature Communications.

[4]  Hong Pan,et al.  Cell/Bacteria‐Based Bioactive Materials for Cancer Immune Modulation and Precision Therapy , 2021, Advanced materials.

[5]  L. Watkins,et al.  Nicotine and its metabolite cotinine target MD2 and inhibit TLR4 signaling , 2021, Innovation.

[6]  Z. Duan,et al.  Targeting macrophages in cancer immunotherapy , 2021, Signal Transduction and Targeted Therapy.

[7]  N. Siemers,et al.  Insights Gained from Single-Cell Analysis of Immune Cells in the Tumor Microenvironment. , 2021, Annual review of immunology.

[8]  E. Chiocca,et al.  HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical Trials , 2020, Cancers.

[9]  R. Muschel,et al.  FGF2 alters macrophage polarization, tumour immunity and growth and can be targeted during radiotherapy , 2020, Nature Communications.

[10]  Kai Yang,et al.  Bacteria-triggered tumor-specific thrombosis to enable potent photothermal immunotherapy of cancer , 2020, Science Advances.

[11]  Yong Wang,et al.  M2-Like Tumor-Associated Macrophage-Targeted Codelivery of STAT6 Inhibitor and IKKβ siRNA Induces M2-to-M1 Repolarization for Cancer Immunotherapy with Low Immune Side Effects , 2020, ACS central science.

[12]  Martha E. Zeeman,et al.  Human chimeric antigen receptor macrophages for cancer immunotherapy , 2020, Nature Biotechnology.

[13]  Frank A. Veliz,et al.  Endosomal toll‐like receptors play a key role in activation of primary human monocytes by cowpea mosaic virus , 2019, Immunology.

[14]  Toshiyuki Shimizu,et al.  Discovery of Novel Small Molecule Dual Inhibitors Targeting Toll-like Receptor 7 and 8. , 2019, Journal of medicinal chemistry.

[15]  N. Steinmetz,et al.  Cowpea Mosaic Virus Promotes Anti‐Tumor Activity and Immune Memory in a Mouse Ovarian Tumor Model , 2019, Advanced therapeutics.

[16]  N. Steinmetz,et al.  Heterologous Prime-Boost Enhances the Antitumor Immune Response Elicited by Plant-Virus-Based Cancer Vaccine. , 2019, Journal of the American Chemical Society.

[17]  A. Sloan,et al.  Plant Virus-Like Particle In Situ Vaccine for Intracranial Glioma Immunotherapy , 2019, Cancers.

[18]  Chengshu Wang,et al.  A small secreted protein triggers a TLR2/4-dependent inflammatory response during invasive Candida albicans infection , 2019, Nature Communications.

[19]  E. Mühlberger,et al.  Toll-like receptor 4 in acute viral infection: Too much of a good thing , 2018, PLoS pathogens.

[20]  N. Steinmetz,et al.  In Situ Vaccination with Cowpea vs Tobacco Mosaic Virus against Melanoma. , 2018, Molecular pharmaceutics.

[21]  R. Weinberg,et al.  Understanding the tumor immune microenvironment (TIME) for effective therapy , 2018, Nature Medicine.

[22]  Xiaoyu Liang,et al.  Chloroquine modulates antitumor immune response by resetting tumor-associated macrophages toward M1 phenotype , 2018, Nature Communications.

[23]  Saguna Verma,et al.  Ebola Virus Glycoprotein Induces an Innate Immune Response In vivo via TLR4 , 2017, Front. Microbiol..

[24]  K. Stacey,et al.  Dengue virus NS1 protein activates immune cells via TLR4 but not TLR2 or TLR6 , 2017, Immunology and cell biology.

[25]  D. Schadendorf,et al.  Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression , 2017, Nature Communications.

[26]  Alberto Mantovani,et al.  Tumour-associated macrophages as treatment targets in oncology , 2017, Nature Reviews Clinical Oncology.

[27]  M. Mandal,et al.  Cancer development, chemoresistance, epithelial to mesenchymal transition and stem cells: A snapshot of IL-6 mediated involvement. , 2016, Cancer letters.

[28]  L. Zitvogel,et al.  Microbiome and Anticancer Immunosurveillance , 2016, Cell.

[29]  P. Savard,et al.  Potentiating Cancer Immunotherapy Using Papaya Mosaic Virus-Derived Nanoparticles. , 2016, Nano letters.

[30]  P. Lizotte,et al.  In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer , 2015, Nature nanotechnology.

[31]  B. Becher,et al.  New insights into IL-12-mediated tumor suppression , 2014, Cell Death and Differentiation.

[32]  N. Itano,et al.  Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment , 2014, Cancers.

[33]  Jeffrey W Pollard,et al.  Tumor-associated macrophages: from mechanisms to therapy. , 2014, Immunity.

[34]  P. Savard,et al.  This information is current as Infection Listeria Monocytogenes Protection from Mediated − T Cell + Enhances CD 8 Nanoparticle Adjuvant Sensing by TLR 7 , 2013 .

[35]  H. Schreiber,et al.  Innate and adaptive immune cells in the tumor microenvironment , 2013, Nature Immunology.

[36]  Y. Li,et al.  Hantaan virus triggers TLR4-dependent innate immune responses. , 2012, Viral immunology.

[37]  N. Tsuchimori,et al.  TAK-242 (Resatorvid), a Small-Molecule Inhibitor of Toll-Like Receptor (TLR) 4 Signaling, Binds Selectively to TLR4 and Interferes with Interactions between TLR4 and Its Adaptor Molecules , 2011, Molecular Pharmacology.

[38]  S. Gordon,et al.  Alternative activation of macrophages: mechanism and functions. , 2010, Immunity.

[39]  S. Akira,et al.  Pattern Recognition Receptors and Inflammation , 2010, Cell.

[40]  F. Balkwill.  Tumour necrosis factor and cancer , 2009, Nature Reviews Cancer.

[41]  Hayyoung Lee,et al.  The structural basis of lipopolysaccharide recognition by the TLR4–MD-2 complex , 2009, Nature.

[42]  L. O’Neill.  Primer: Toll-like receptor signaling pathways—what do rheumatologists need to know? , 2008, Nature Clinical Practice Rheumatology.

[43]  R. Jain,et al.  The role of nitric oxide in tumour progression , 2006, Nature Reviews Cancer.

[44]  Douglas T. Golenbock,et al.  Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus , 2000, Nature Immunology.